智通财经网·2026-02-27 10:39Group 1 - The company Fudan Zhangjiang (01349) reported a revenue of approximately 686 million yuan for 2025, representing a year-on-year decrease of 3.33% [1] - The net loss attributable to shareholders was approximately 157 million yuan, marking a shift from profit to loss compared to the previous year, with a basic loss per share of 0.15 yuan [1] Group 2 - The company actively promoted the progress of R&D projects, with R&D investment accounting for an increasing proportion of revenue, totaling approximately 358 million yuan during the reporting period [2] - The Phase III clinical trial for the FDA018 antibody-drug conjugate for triple-negative breast cancer exceeded enrollment expectations, with over 350 participants enrolled, and data collection is currently underway [2] - The Phase II clinical study for the FDA022 antibody-drug conjugate targeting HER2 low-expressing breast cancer has completed enrollment, and a communication meeting with regulatory authorities was held during the reporting period [2] Group 3 - The company's production and operations remained normal, with no changes in the main types of drugs sold [3] - Due to the inclusion of Doxorubicin Liposome Injection in the national procurement catalog, the company's product, Liposome Doxorubicin, was not selected, prompting a strategic adjustment in its sales approach, including a gradual price reduction starting May 1, 2025, which led to a decrease in profit margins [3]